Is Bio-Techne Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Bio-Techne Corp. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is considered overvalued based on its high P/E ratio of 37, a Price to Book Value of 3.78, and an EV to EBITDA of 20.54. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of 19.09 and 15.17, respectively, highlighting the relative overvaluation of Bio-Techne.
Despite a recent strong performance with a 1-week return of 5.46% compared to the S&P 500's 1.70%, the longer-term outlook remains concerning, with a YTD return of -14.12% versus the S&P 500's 13.30%. This suggests that while there may be short-term gains, the overall valuation metrics indicate that Bio-Techne Corp. is overvalued in the current market context.